- Home
- Peptides
- Neuropeptides
- Vasopressin
What Is Vasopressin? Benefits, Research & Safety
A hormone essential for water balance and blood pressure regulation, also involved in social behavior and stress responses.
UK summary: Endogenous hormone. Synthetic analogues (vasopressin itself for vasopressor / GI bleeding use; desmopressin for diabetes insipidus and nocturnal enuresis) are UK prescription-only medicines. Prohibited under WADA S5 (diuretics / masking agents).
Quick Facts
In This Guide
Overview
Vasopressin — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Endogenous hormone. Synthetic analogues (vasopressin itself for vasopressor / GI bleeding use; desmopressin for diabetes insipidus and nocturnal enuresis) are UK prescription-only medicines. Prohibited under WADA S5 (diuretics / masking agents).
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
- EU: Approved for similar indications across member states.
- Notes: Vasopressin and analogues have well-established approved uses. Desmopressin is widely available. Use for behavioural modification or social enhancement is not approved and remains investigational.
05Approved medical uses
- Diabetes insipidus (desmopressin — MHRA-licensed POM).
- Nocturnal enuresis (desmopressin — licensed POM).
- Vasopressor support in shock (vasopressin IV — hospital use).
06Unapproved / promotional claims
- 'Memory peptide' supplements.
- Social-cognition enhancer for healthy adults.
07Common internet claims
- Nasal-vasopressin marketed by biohacker forums as a memory-enhancing nootropic.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Vasopressin supplements improve memory or focus” | E | No | High | Native vasopressin is degraded orally; nasal vasopressin is a UK POM and not appropriate for self-administration. |
09Safety uncertainty score
Safety profile partly characterised; some signals from observational or preclinical data.
10Known adverse signals
- Hyponatraemia risk (especially with fluid intake combined with desmopressin).
- Cardiovascular effects (BP, vasoconstriction).
- Contraindications include cardiovascular disease, hyponatraemia, SIADH.
11Drug-interaction uncertainty
Some interaction data published; check with a prescriber for your specific medicines.
12Anti-doping status
13UK legal position
Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
14EU legal position
Approved for similar indications across member states.
15What this page cannot tell you
- Whether a grey-market nasal-vasopressin product contains the labelled compound at the labelled concentration.
- Whether off-label cognitive-enhancement use is safe long-term.
16Last reviewed
17Citation quality score
18Research gaps
- Cognitive-enhancement RCTs in healthy adults are limited; replication poor.
19Safer alternatives / established care pathways
- GP review for any genuine memory or focus concern.
- Adult ADHD assessment if attention is the issue.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is vasopressin (or desmopressin) appropriate for my situation?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Effective treatment for central diabetes insipidus (as desmopressin)
- 2Management of nocturnal enuresis/bedwetting (desmopressin)
- 3Treatment of von Willebrand disease (desmopressin)
- 4Vasopressor support in septic shock
- 5Cardiac arrest protocols
- 6Research into social behaviour modulation
- 7Potential applications in psychiatric conditions (investigational)
Claim vs Evidence
How popular claims about Vasopressin stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Vasopressin supplements improve memory or focus” | E | No | High | Native vasopressin is degraded orally; nasal vasopressin is a UK POM and not appropriate for self-administration. |
Theoretical Dosing & Protocols
| Theoretical Dosage | Varies greatly by indication and analogue used |
| Frequency | Indication-dependent; from once daily to continuous infusion |
| Duration | Chronic for diabetes insipidus; acute for critical care |
| Notes | Vasopressin and its analogues (especially desmopressin) have established medical uses. Use must be under medical supervision with appropriate monitoring. Water intake restriction may be necessary to prevent water intoxication. |
Administration Routes
Routes studied in research settings (educational only):
- Intravenous (critical care, severe diabetes insipidus)
- Subcutaneous (some protocols)
- Intranasal (desmopressin for diabetes insipidus, bedwetting)
- Oral (desmopressin tablets available)
| Half-Life | Stability |
|---|---|
| 10-20 minutes in plasma (vasopressin); longer for desmopressin | Injectable solutions per manufacturer specifications; desmopressin formulations have defined stability |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Water retention
- Headache
- Nausea
- Abdominal cramps
- Nasal congestion (intranasal route)
- Hypertension (vasopressin)
Rare Risks & Concerns
- Water intoxication and hyponatraemia (serious)
- Seizures from hyponatraemia
- Cardiac ischaemia (vasoconstriction)
- Allergic reactions
Contraindications
- Conditions with fluid/electrolyte imbalances
- Coronary artery disease (relative)
- Hyponatraemia
- Polydipsia or inappropriate thirst mechanisms
UK & EU Regulatory Context
🇬🇧 United Kingdom
Vasopressin and desmopressin licensed for various indications including diabetes insipidus, nocturnal enuresis, and haemostasis.
🇪🇺 European Union
Approved for similar indications across member states.
Clinical Studies Summary
Desmopressin for Diabetes Insipidus
Extensive clinical experience confirming desmopressin as first-line treatment for central diabetes insipidus.
Vasopressin in Septic Shock
Trials including VASST and VANISH investigating vasopressin in vasodilatory shock.
Looking for Vasopressin?
Source research-grade Vasopressin from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Vasopressin
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is vasopressin (or desmopressin) appropriate for my situation?
UK regulatory & safety context
Related Peptides
Oxytocin
A natural hormone and neurotransmitter involved in social bonding, childbirth, lactation, and emotional regulation with therapeutic applications.
Learn moreACTH
A pituitary hormone that stimulates cortisol production, used diagnostically and therapeutically for various conditions including infantile spasms.
Learn moreVIP
A neuropeptide with vasodilatory, anti-inflammatory, and immunomodulatory properties, researched for various therapeutic applications.
Learn more